Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Operating Leases (2019 - 2025)

Historic Operating Leases for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $15.1 million.

  • Keros Therapeutics' Operating Leases fell 2164.78% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year decrease of 2164.78%. This contributed to the annual value of $16.9 million for FY2024, which is 2562.69% up from last year.
  • Latest data reveals that Keros Therapeutics reported Operating Leases of $15.1 million as of Q3 2025, which was down 2164.78% from $15.7 million recorded in Q2 2025.
  • Keros Therapeutics' Operating Leases' 5-year high stood at $19.3 million during Q3 2024, with a 5-year trough of $231000.0 in Q4 2021.
  • In the last 5 years, Keros Therapeutics' Operating Leases had a median value of $13.7 million in 2023 and averaged $11.3 million.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 6502.89% in 2021, then skyrocketed by 548441.56% in 2022.
  • Keros Therapeutics' Operating Leases (Quarter) stood at $231000.0 in 2021, then soared by 5484.42% to $12.9 million in 2022, then rose by 4.18% to $13.4 million in 2023, then increased by 25.63% to $16.9 million in 2024, then decreased by 10.5% to $15.1 million in 2025.
  • Its last three reported values are $15.1 million in Q3 2025, $15.7 million for Q2 2025, and $16.3 million during Q1 2025.